// startup autopsy
AmpliMed Corporation
Two decades of antivascular oncology that couldn't cross the efficacy threshold
marketfitSlow Death
Years-long decline before final shutdown · Fatal mistake: AmpliMed persisted with antivascular cancer therapy for over two decades without generating the pivotal clinical data needed to attract a pharma acquirer or large licensing deal.
Key Events Timeline
FOUNDING
AmpliMed Corporation founded in Arizona to research antivascular approaches to cancer treatment.
FUNDING
Secured early funding rounds supporting preclinical antivascular compound development.
PRODUCT LAUNCH
Advanced lead antivascular compound into Phase I clinical trials, marking first human studies.
FUNDING
Raised final funding bringing total to $14.1M, insufficient for a fully powered Phase II oncology trial.
SHUTDOWN
AmpliMed closes after 23 years, unable to generate pivotal data or secure pharma partnership.